Literature DB >> 34618249

Predictors of visual and endocrine outcomes after endoscopic transsphenoidal surgery for pituitary adenomas.

Mendel Castle-Kirszbaum1, Yi Yuen Wang2, James King3, Tony Goldschlager4,5.   

Abstract

Surgery for pituitary adenoma is indicated for relief of mass effect and control of endocrinopathy. Setting benchmarks for visual and hormonal outcomes is important for monitoring performance of surgical centres, while understanding the preoperative factors that predict endocrine cure and visual improvement facilitates tailored counselling for patients prior to surgery. A prospective, consecutive cohort of surgically managed (endoscopic transsphenoidal) pituitary adenoma (n = 304) were analysed. Preoperative and postoperative endocrine and visual field assessments were performed and compared to demographic, imaging and pathological data. Larger adenomas tended to have preoperative endocrine deficiency (p < 0.001) and visual field defects (p < 0.001). The largest tumours did not experience normalisation of their endocrinopathy or visual fields with surgery. Of the adenomas with normal preoperative endocrine function, 92.0% (126/137) maintained this postoperatively; only 2 of the 11 patients with new hypopituitarism required long-term hormone replacement. Functional tumour cure was achieved in 65.2% (86/116) after surgery; 74.4% (32/43) of acromegalics and 70.0 (35/50) of Cushing's disease patients achieved hormonal control. All patients with isolated hyperprolactinaemia from stalk effect normalised with surgery, while only 15.9% (7/44) with hypopituitarism recovered normal endocrine function. New hypopituitarism was predicted by younger age and functional adenoma, particularly Cushing's disease. Resolution of endocrinopathy was less likely with reoperative cases and those with cavernous sinus invasion (Knosp grade > 2) or preoperative ophthalmoplegia. One-third of the cohort (102/304, 33.6%) had a preoperative field cut, most commonly an incomplete (51.0%) or complete (31.4%) bitemporal hemianopsia. Only two patients (2/304, 0.7%) had visual field worsening after surgery, while 71.6% (73/102) experienced partial or complete resolution of their field cut after surgery. Complete resolution of visual field defect was predicted by younger age and incomplete bitemporal hemianopsia. Surgery is a safe and effective therapy for pituitary adenomas. Nearly all patients experience improvement in visual fields, especially the young and those with incomplete bitemporal defects. Reoperative cases and those with cavernous sinus involvement (high Knosp grade/ophthalmoplegia) are less likely to have resolution of endocrinopathy. Visual worsening, new ophthalmoplegia or endocrinopathy were rare complications of surgery.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Adenoma; Endocrine; Outcome; Pituitary; Transsphenoidal; Vision

Mesh:

Year:  2021        PMID: 34618249     DOI: 10.1007/s10143-021-01617-y

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  28 in total

1.  Predictors of visual and endocrine outcomes after endoscopic transsphenoidal surgery for pituitary adenomas.

Authors:  Mendel Castle-Kirszbaum; Yi Yuen Wang; James King; Tony Goldschlager
Journal:  Neurosurg Rev       Date:  2021-08-09       Impact factor: 3.042

2.  Endoscopic endonasal transsphenoidal surgery.

Authors:  Paolo Cappabianca; Luigi Maria Cavallo; Enrico de Divitiis
Journal:  Neurosurgery       Date:  2004-10       Impact factor: 4.654

3.  Transsphenoidal neurosurgery of intracranial neoplasm.

Authors:  J Hardy; J L Vezina
Journal:  Adv Neurol       Date:  1976

4.  Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings.

Authors:  E Knosp; E Steiner; K Kitz; C Matula
Journal:  Neurosurgery       Date:  1993-10       Impact factor: 4.654

5.  Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.

Authors:  Richard N Clayton; Peter W Jones; Raoul C Reulen; Paul M Stewart; Zaki K Hassan-Smith; Georgia Ntali; Niki Karavitaki; Olaf M Dekkers; Alberto M Pereira; Mark Bolland; Ian Holdaway; Jorgen Lindholm
Journal:  Lancet Diabetes Endocrinol       Date:  2016-06-02       Impact factor: 32.069

6.  Mortality in acromegaly: a metaanalysis.

Authors:  O M Dekkers; N R Biermasz; A M Pereira; J A Romijn; J P Vandenbroucke
Journal:  J Clin Endocrinol Metab       Date:  2007-10-30       Impact factor: 5.958

7.  Quality of life in patients with a pituitary adenoma.

Authors:  Michelle D Johnson; C J Woodburn; Mary Lee Vance
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

8.  What surgeons tell patients and what patients want to know before major cancer surgery: a qualitative study.

Authors:  Angus G K McNair; F MacKichan; J L Donovan; S T Brookes; K N L Avery; S M Griffin; T Crosby; J M Blazeby
Journal:  BMC Cancer       Date:  2016-03-31       Impact factor: 4.430

9.  Frailty does not preclude surgical success after endoscopic transsphenoidal surgery for pituitary adenomas.

Authors:  Mendel Castle-Kirszbaum; Yi Yuen Wang; James King; Tony Goldschlager
Journal:  Pituitary       Date:  2021-06-25       Impact factor: 4.107

View more
  4 in total

1.  Surgical outcomes and quality of life in Rathke's cleft cysts undergoing endoscopic transsphenoidal resection: a multicentre study and systematic review of the literature.

Authors:  Mendel Castle-Kirszbaum; Jeremy Kam; Yi Yuen Wang; James King; Kylie Fryer; Tony Goldschlager
Journal:  Pituitary       Date:  2022-01-10       Impact factor: 4.107

2.  Predictors of visual and endocrine outcomes after endoscopic transsphenoidal surgery for pituitary adenomas.

Authors:  Mendel Castle-Kirszbaum; Yi Yuen Wang; James King; Tony Goldschlager
Journal:  Neurosurg Rev       Date:  2021-08-09       Impact factor: 3.042

3.  Diabetes insipidus after endoscopic transsphenoidal surgery: multicenter experience and development of the SALT score.

Authors:  Mendel Castle-Kirszbaum; Peter Fuller; Yi Yuen Wang; James King; Tony Goldschlager
Journal:  Pituitary       Date:  2021-05-26       Impact factor: 4.107

4.  Frailty does not preclude surgical success after endoscopic transsphenoidal surgery for pituitary adenomas.

Authors:  Mendel Castle-Kirszbaum; Yi Yuen Wang; James King; Tony Goldschlager
Journal:  Pituitary       Date:  2021-06-25       Impact factor: 4.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.